Life Technologies says its tech is 100 times more potent; Synairgen to get Japanese patent for inhaled drugs;

> Life Technologies has developed new drug delivery technology for therapeutic applications that's 100 times more potent than previous formulations, the company says. Story

> Synairgen, based in the U.K., is expected to receive a Japanese patent for its inhaled interferon beta as a treatment for rhinovirus infections in asthma and COPD patients. Local delivery of IFN-beta to the lungs could limit the spread of virus to lungs. Item

> Euclid Systems will partner with Ora to conduct pre-clinical and clinical development of its collagen-based drug delivery system for treatment of glaucoma. Release

> Biopath Holdings, a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, is relocating its corporate headquarters to Houston. Announcement

> Advanced Injection Devices: Developments, Drivers and Directions for the Future. Report by Andy Fry, founder and director of Team Consulting in the UK. PDF of report

> So you want to use a carbon nanotube as a needle. The thing is, are they better for delivering injections or for collecting blood samples? Scientists find out. Release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.